6 Best Peptides for Energy

What to Know Before Choosing a Peptide for Energy

The word "energy" covers a lot of ground. In the context of peptide therapy, it refers to several distinct biological phenomena: mitochondrial ATP production, growth hormone-driven metabolic recovery, fat oxidation, cognitive stamina, and cellular repair. The compounds people reach for depend on which part of that picture they are trying to address, and no single compound covers all of it.

Every compound in this guide earned its place because people actually use it or are actively discussing using it for energy and fatigue. That is the whole test for inclusion. Whether a compound is FDA-approved, whether it has randomized controlled trial data, and whether it is sold at a pharmacy are not the criteria here. FDA-approved compounds, telemedicine-prescribed compounds, and research-only compounds are all represented, and for each one the evidence is described honestly rather than used as a filter for inclusion. A compound with only community-reported experience still belongs on this list, with that thin evidence stated plainly.

The entries are numbered, but the numbers are a spine for the list, not a verdict. The order reflects how prominently each compound appears in research and in real-world use, not a recommendation that one is better than another for your situation. The right choice depends on your goal, your health history, and what you build with the app. Before making any decision, consult a qualified healthcare professional.

1. SS-31 (Elamipretide): Repairing Mitochondrial Machinery at the Source

SS-31, also called Elamipretide and sometimes referred to by the brand name LAMHYR in clinical contexts, is a synthetic tetrapeptide that targets energy production where it actually happens: inside the mitochondria. Most compounds described as energy-boosting work indirectly or upstream. SS-31 works at the inner mitochondrial membrane itself, which is what makes it mechanistically distinct from everything else on this list.

The way it works comes down to a phospholipid called cardiolipin, which sits almost exclusively on the inner mitochondrial membrane. Think of that membrane as a dam wall holding back a proton gradient, and cardiolipin as the structural material that keeps the wall intact. When the membrane degrades, protons leak through instead of flowing through the energy-generating machinery, and ATP production drops. SS-31 binds directly to cardiolipin, stabilizes the membrane structure, and stops those leaks. The electron transport chain then runs more efficiently, more potential energy converts to ATP rather than waste heat, and the cell's capacity to meet energy demand increases. SS-31 also enhances ADP sensitivity through a protein called the adenine nucleotide translocator, which allows the mitochondria to ramp up ATP synthesis faster when energy demand rises.

In terms of published human evidence, SS-31 stands alone in this field. It received FDA accelerated approval in September 2025 for Barth syndrome, a rare genetic disease affecting the mitochondria and heart. The approval followed a completed Phase 2 randomized controlled trial in which improved exercise tolerance was the primary endpoint. The compound was found safe and well-tolerated across all doses studied, with the most commonly reported side effects being mild injection pain and occasional headache. That approval is specific to Barth syndrome in patients meeting defined criteria, not to general energy enhancement or chronic fatigue in otherwise healthy adults. For off-label use in energy and fatigue, SS-31 is in investigational territory with no human trial data comparable to the Barth syndrome trial published for that application.

Real-world accounts from community forums, particularly from people dealing with chronic fatigue, ME/CFS, and long COVID, are among the most consistently positive of any compound discussed for energy. Users frequently describe a qualitative shift after a few days of use: they notice they are simply not tired at 5 p.m. anymore. The experience is less a sharp spike and more a sustained absence of fatigue. For some users the effect is described as all or nothing, significant improvement or none at all, with variability that community members themselves attribute to differences in baseline mitochondrial health. SS-31 is available by prescription only for its approved indication through specialty pharmacies. Off-label access operates through separate channels with different considerations.

2. MOTS-c: Activating the Cell's Master Energy Sensor

MOTS-c is a mitochondrial-derived peptide, encoded not by the nuclear genome but by the mitochondrial genome itself, which makes it unusual among signaling peptides. It acts as a messenger from the mitochondria to the rest of the cell, and its primary target is AMPK, often described as the cell's master energy sensor.

Here is how that works. When MOTS-c is active, it transiently disrupts a metabolic pathway called the folate cycle, which shifts the ratio of AMP to ATP inside the cell. AMPK reads that shift as a signal that energy supplies are running low and responds by switching the cell into an energy-production mode. One of the most important downstream effects is the upregulation of PGC-1 alpha, a transcription factor that drives mitochondrial biogenesis, which is the creation of new mitochondria. More mitochondria means more capacity to generate ATP, which is why people who respond to MOTS-c describe energy improvements that build gradually over weeks rather than arriving as an immediate hit.

No published randomized controlled trial results exist for MOTS-c in humans as of 2026. Two clinical trials are registered, but their results have not been published, and those trials focus on metabolic conditions rather than on energy or fatigue outcomes in healthy adults. Some sources have described MOTS-c as having strong human exercise data, but that claim is inconsistent with the actual clinical picture, which shows no published human RCTs for this use. What exists is animal and cell data, mechanistic work, and an active community of users reporting their experiences.

Among those community accounts, MOTS-c generates some of the more enthusiastic responses in the energy space. Users describe a clean, sharp energy that feels qualitatively different from caffeine, improved endurance during sustained cardio, and a reduction in the midday energy wall. Some report a noticeable effect within 20 to 30 minutes of a subcutaneous injection. Others describe a slower build over the first two to four weeks before a steady energy baseline takes shape. Experienced users consistently note that subcutaneous injection appears to be the only effective route, with oral forms reported as ineffective due to digestive breakdown. A meaningful number of users report no results at all, attributing this to batch quality variation, individual differences in mitochondrial baseline, or the likelihood that the compound matters more to someone who is metabolically compromised than to someone already functioning optimally. MOTS-c is classified as a research chemical and is not available through compounding pharmacies in the US.

3. CJC-1295 and Ipamorelin: Growth Hormone Support for Metabolic Recovery

CJC-1295 and Ipamorelin are nearly always discussed together because they work through two different but complementary mechanisms to stimulate the body's own growth hormone production, and combining them produces a stronger and more physiologically natural GH pulse than either one alone.

CJC-1295 is an analog of growth hormone-releasing hormone (GHRH), the signal the hypothalamus sends to the pituitary to prompt GH release. It binds to GHRH receptors and amplifies that signal. Ipamorelin is a ghrelin mimetic, a compound that activates the ghrelin receptor and triggers a separate GH-release pathway. Because they work through different receptors leading to the same output, their effects on GH and, downstream, on IGF-1 (insulin-like growth factor 1) are additive. Elevated GH and IGF-1 support tissue repair, increase metabolic rate, improve fat oxidation, and enhance sleep quality. Sleep is worth singling out here because better slow-wave sleep is one of the primary routes by which this combination affects energy: deeper recovery overnight translates to more available energy the next day.

Human randomized controlled trial data exists for the GH secretion pharmacology of this combination, meaning researchers have measured how these compounds alter GH pulses and for how long. What does not exist is controlled trial evidence directly measuring energy or fatigue as outcomes in healthy adults. The connection from increased GH and IGF-1 to improved energy is mechanistically supported and widely applied in functional medicine practice, but it is extrapolated rather than directly tested in a controlled energy trial. Compounded versions of CJC-1295 are available via prescription through licensed clinicians in the US, which puts this combination in a different access category from the research-chemical compounds on this list.

Community accounts consistently describe this combination as a foundational approach for people dealing with age-related energy decline and metabolic fatigue. The effects are reported as gradual and cumulative rather than immediate, typically showing up as better sleep, improved morning energy, steadier metabolic function over weeks of use, and easier body composition maintenance. People who use this combination for energy tend to frame it in terms of restoring a baseline that age or stress had eroded rather than getting a boost above that baseline.

4. NAD+ (Nicotinamide Adenine Dinucleotide): Cellular Energy Currency Replenishment

NAD+ sits upstream of the mitochondria as a coenzyme that the entire energy production system depends on. It is the molecule that shuttles electrons through the chain of reactions that ultimately generate ATP, and it is also the substrate for sirtuins and PARPs, two families of enzymes that regulate cellular repair, stress response, and metabolic function. Without adequate NAD+, the electron transport chain cannot run at full efficiency, and cells lose capacity to meet energy demand. NAD+ levels decline with age, and that decline correlates with reduced energy and metabolic capacity in older adults.

One note for transparency: NAD+ is technically a coenzyme rather than a peptide. It is included here because it is consistently grouped with these compounds in practice, often administered similarly through injection, and targets the same overlapping mitochondrial pathways. The next entry covers 5-Amino-1MQ, which raises intracellular NAD+ by a different mechanism. The two are related but distinct approaches to the same upstream problem.

Early human randomized controlled trials have been published for NAD+ and its precursors, making this evidence base more developed than MOTS-c or 5-Amino-1MQ, though still far from definitive for energy in healthy adults. Intravenous NAD+ administration has shown improvements in fatigue and alertness markers in studied populations. Oral precursors such as NMN and NR have produced mixed results on metabolic markers in early trials. The populations studied lean toward metabolic conditions rather than general energy optimization in healthy people, so translation to that use is inferred rather than directly established by a controlled trial.

Among community users, NAD+ carries a reputation for being particularly meaningful for people dealing with chronic fatigue or significant age-related energy decline. Accounts range from transformative for people at the more depleted end of the spectrum to a more subtle productivity and clarity improvement for those starting from a healthier baseline. NAD+ precursors in supplement form are widely available. IV NAD+ is offered in some clinical settings. Neither is FDA-approved as a drug for energy enhancement, and the most pronounced effects reported anecdotally tend to come from the injectable route rather than oral supplementation.

5. 5-Amino-1MQ: Raising Intracellular NAD+ Through a Different Mechanism

5-Amino-1MQ (5-amino-1-methylquinolinium) takes an indirect route to the same destination that NAD+ targets directly. Rather than supplying NAD+ from outside the cell, it blocks an enzyme called NNMT (nicotinamide N-methyltransferase). NNMT consumes NAD+ as part of its normal activity and tends to be more active in metabolically dysregulated states. By inhibiting NNMT, 5-Amino-1MQ reduces that unnecessary consumption and allows intracellular NAD+ levels to rise on their own, which in turn increases metabolic rate and promotes fat oxidation.

Like NAD+, 5-Amino-1MQ is technically a small molecule rather than a peptide. It is consistently grouped with peptide-adjacent compounds because it targets the same metabolic and mitochondrial pathways and is discussed in the same communities. The mechanistic rationale for its energy effects comes primarily from cell and animal studies. No published human randomized controlled trial data exists for 5-Amino-1MQ in energy outcomes as of 2026. The evidence is preclinical, and what fills the space beyond that is community-reported experience from users who have incorporated it into protocols focused on metabolic energy and fat loss.

User accounts tend to describe the energy effects of 5-Amino-1MQ as more subtle compared to MOTS-c or SS-31. What gets mentioned more consistently is a reduction in afternoon energy crashes, decreased reliance on caffeine, and a sense of cognitive sharpness alongside the metabolic effects. Some users notice increased energy relatively quickly after starting. The more prominent outcome in community forums is the metabolic and body composition effect rather than a dramatic energy surge, and users who approach it primarily as an energy compound tend to be less impressed than those who see it as a metabolic support tool with energy as one benefit among several. It is sold as a research chemical and is not available through compounding pharmacies.

6. Sermorelin: The Gradual Growth Hormone Approach for Age-Related Fatigue

Sermorelin is a GHRH analog that occupies a distinct position in this field because of how it is used and how it is accessed. Where CJC-1295 is typically combined with Ipamorelin to produce a stronger GH pulse, Sermorelin is often used as a standalone compound for people who want a more gradual and physiologically gentle approach to restoring GH levels, particularly in the context of age-related fatigue and declining vitality.

The mechanism is straightforward: Sermorelin binds to GHRH receptors in the pituitary and hypothalamus and stimulates the natural pulsatile release of growth hormone. Unlike injectable synthetic GH, which essentially overrides the body's own rhythm, Sermorelin works with the pituitary's existing feedback system to amplify the signal that is already there. A useful way to think about it is the difference between playing recorded music at maximum volume and simply turning up the gain on the original source. The downstream effects, improved fat metabolism, better tissue repair, enhanced sleep quality, and the energy improvements that follow from those, build over weeks of consistent use rather than appearing immediately.

The evidence base for Sermorelin parallels that of the CJC-1295 and Ipamorelin combination: there is human data on GH secretion pharmacology, but direct controlled evidence for energy outcomes in healthy adults is limited. The extrapolation from GH restoration to improved energy is mechanistically sound and widely applied in clinical practice, but it has not been tested in a controlled trial with energy as the primary endpoint. Patients who use Sermorelin through a prescribing clinician, where it is available as a compounded prescription in the US subject to current regulatory conditions, often describe effects in terms of vitality restoration rather than acute energy: steadier energy across the day, better sleep, and a return to a metabolic baseline that had eroded with age. Access requires a prescription from a licensed clinician.

How These Peptides Compare

Frequently Asked Questions

Are these compounds legal to use for energy?

Legal status varies significantly by compound. SS-31 is FDA-approved for a specific indication and is available by prescription through specialty pharmacies. Sermorelin and CJC-1295 combined with Ipamorelin are available as compounded prescriptions from licensed clinicians in the US, though the regulatory landscape for compounded peptides continues to evolve. MOTS-c and 5-Amino-1MQ are classified as research chemicals, sold legally as such but labeled not for human use. NAD+ precursors are available as dietary supplements, and IV NAD+ is offered in some clinical settings. None of these compounds is approved by the FDA for general energy enhancement in healthy adults, and anyone considering them should consult a healthcare professional and understand the regulatory status in their jurisdiction.

How long before these compounds show results?

Onset varies by compound and by the individual. SS-31 users frequently notice a change within a few days, particularly a reduction in late-afternoon fatigue. MOTS-c responses range from an acute effect within roughly 30 minutes of injection for some users to a gradual baseline shift that takes two to four weeks to stabilize for others. The GH secretagogues, Sermorelin and the CJC-1295 and Ipamorelin combination, work cumulatively and typically show effects over several weeks as GH and IGF-1 levels rebuild. Because none of these has been tested in large randomized controlled trials with energy as a primary endpoint, there is no clinically established timeline; what exists is what the community has reported, and individual variability is high.

Do these compounds work the same way for everyone?

No, and the community is candid about this. A meaningful number of users report no perceptible effect despite correct administration, and this is particularly noted with MOTS-c. The most commonly proposed explanations are individual differences in baseline mitochondrial health, batch quality variation in research-chemical sources, and the possibility that the effect is smaller for someone already functioning at a healthy metabolic baseline. SS-31 is described by some users as all or nothing, with significant benefit in people whose fatigue has a mitochondrial component and little perceptible effect otherwise. The compounds most consistently discussed as relevant for people who are metabolically compromised or managing chronic fatigue tend to be SS-31, MOTS-c, and NAD+.

Is SS-31 only for people with Barth syndrome?

The FDA approval is specific to Barth syndrome. Off-label use of SS-31 for general energy and fatigue exists and is actively discussed in communities including people managing ME/CFS, long COVID, and chronic fatigue of other origins, but it is investigational in those contexts. No randomized controlled trial data comparable to the Barth syndrome trial has been published for energy outcomes in otherwise healthy adults, and anyone pursuing SS-31 outside the approved indication would be doing so experimentally with appropriate medical guidance as the necessary starting point.

What are the main safety considerations for these compounds?

SS-31 was found safe and well-tolerated across all doses studied in clinical trials, with mild injection pain and occasional headache as the most commonly reported effects. For the other compounds, the safety picture is less formally established. MOTS-c users report mild injection-site burning and rare temporary skin reactions. Compounds available only as research chemicals have no formally validated human safety profile, and long-term data is limited across the board. General risks associated with any injectable compound, including infection from non-sterile technique and the possibility of contamination in unregulated research-chemical sources, apply regardless of which specific compound is being considered. A prescribing clinician is the appropriate person to assess individual safety before beginning any of these.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for energy in one place.